Go Pro

Mativ (NYSE:MATV) Shares Gap Up on Better-Than-Expected Earnings

Mativ logo with Materials background
Image from MarketBeat Media, LLC.

Key Points

  • Mativ beat quarterly expectations, reporting earnings per share of $0.50 versus the $0.28 consensus estimate and revenue of $531.8 million compared with forecasts of $508.5 million.
  • The earnings surprise drove the stock sharply higher: shares opened at $10.74 versus a prior close of $9.57 and were last reported up 17.7% at $11.14.
  • Mativ declared a quarterly dividend of $0.10, equivalent to $0.40 annually and a 3.5% yield. Despite institutional ownership of nearly 95%, analysts’ consensus rating remains “Reduce.”
  • MarketBeat previews top five stocks to own in September.

Shares of Mativ Holdings, Inc. (NYSE:MATV - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $9.57, but opened at $10.74. Mativ shares last traded at $11.1370, with a volume of 117,474 shares traded.

The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.22. Mativ had a return on equity of 11.77% and a net margin of 3.86%.The business had revenue of $531.80 million during the quarter, compared to analysts' expectations of $508.50 million.

Mativ Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Friday, August 28th will be paid a $0.10 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.40 dividend on an annualized basis and a yield of 3.5%. Mativ's dividend payout ratio is 29.85%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on MATV shares. Wall Street Zen downgraded shares of Mativ from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Weiss Ratings upgraded shares of Mativ from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce".

Get Our Latest Analysis on MATV

Institutional Investors Weigh In On Mativ

A number of hedge funds and other institutional investors have recently bought and sold shares of MATV. Millennium Management LLC grew its stake in Mativ by 1,978.4% during the 1st quarter. Millennium Management LLC now owns 996,673 shares of the company's stock worth $6,209,000 after buying an additional 948,720 shares during the last quarter. UBS Group AG raised its stake in Mativ by 144.9% in the third quarter. UBS Group AG now owns 688,273 shares of the company's stock valued at $7,784,000 after buying an additional 407,275 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in Mativ in the second quarter worth about $2,450,000. Zacks Investment Management purchased a new stake in shares of Mativ during the third quarter worth about $3,561,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in shares of Mativ by 376.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 350,575 shares of the company's stock valued at $3,965,000 after acquiring an additional 277,021 shares in the last quarter. Hedge funds and other institutional investors own 94.95% of the company's stock.

Mativ Trading Up 17.7%

The stock has a market cap of $621.06 million, a price-to-earnings ratio of 8.38 and a beta of 0.87. The company has a debt-to-equity ratio of 2.22, a current ratio of 2.26 and a quick ratio of 1.12. The company's fifty day moving average price is $8.03 and its 200-day moving average price is $9.51.

Mativ Company Profile

(Get Free Report)

Mativ is a global supplier of specialty fiber-based materials and engineered solutions, established in April 2021 through the spin-off of Ahlstrom-Munksjö’s global filtration and engineered materials business. Trading on the New York Stock Exchange under the ticker MATV, the company focuses on designing and manufacturing high-performance products for a broad range of end markets, including life sciences, energy storage, industrial filtration, and consumer products.

Through its Advanced Solutions segment, Mativ produces innovative materials such as lithium-ion battery separators, specialty release liners, and pressure-sensitive adhesive tapes.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Mativ Right Now?

Before you consider Mativ, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mativ wasn't on the list.

While Mativ currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines